{"id":"gefapixant-citrate","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"P2X purinoceptor 3","category":"target"},{"label":"P2RX3","category":"gene"},{"label":"R05DB29","category":"atc"},{"label":"Active","category":"status"},{"label":"Refractory chronic cough","category":"indication"},{"label":"Msd K.K.","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Msd K.K.","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=GEFAPIXANT CITRATE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:52:26.352614+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:52:32.622352+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GEFAPIXANT CITRATE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:52:33.645439+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: P2X purinoceptor 3 antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:52:34.379974+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4594278/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:52:34.283038+00:00"}},"allNames":"lyfnua","offLabel":[],"synonyms":["gefapixant","gefapixant citrate","lyfnua","AF-219","RO4926219","MK-7264"],"timeline":[{"date":"2022-01-20","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Msd K.K.)"}],"brandName":"Lyfnua","ecosystem":[{"indication":"Refractory chronic cough","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"P2X purinoceptor 3","targets":[{"gene":"P2RX3","source":"DrugCentral","target":"P2X purinoceptor 3","protein":"P2X purinoceptor 3"}],"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Lyfnua acts as a selective antagonist of the P2X3 receptor, a subtype of purinergic receptor that plays a key role in the transmission of cough and pain signals in the respiratory tract."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5519","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=GEFAPIXANT%20CITRATE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GEFAPIXANT CITRATE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T02:40:00.366712","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:52:36.219693+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"benzonatate","drugSlug":"benzonatate","fdaApproval":"1958-02-10","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"pentoxyverine","drugSlug":"pentoxyverine","fdaApproval":"","relationship":"same-class"},{"drugName":"clofedanol","drugSlug":"clofedanol","fdaApproval":"","relationship":"same-class"}],"genericName":"gefapixant citrate","indications":{"approved":[{"name":"Refractory chronic cough","source":"DrugCentral","snomedId":2561000112106,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"benzonatate","brandName":"benzonatate","genericName":"benzonatate","approvalYear":"1958","relationship":"same-class"},{"drugId":"pentoxyverine","brandName":"pentoxyverine","genericName":"pentoxyverine","approvalYear":"","relationship":"same-class"},{"drugId":"clofedanol","brandName":"clofedanol","genericName":"clofedanol","approvalYear":"","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06542484","phase":"NA","title":"The Real-world Treatment Satisfaction by Gefapixiant in RCC","status":"RECRUITING","sponsor":"Nagoya City University","startDate":"2024-12-04","conditions":["Chronic Cough"],"enrollment":63,"completionDate":"2026-06-30"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"6K6L7E3F1L","INN_ID":"10642","UMLSCUI":"C5139827","chemblId":"CHEMBL4594278","ChEMBL_ID":"CHEMBL3716057","KEGG_DRUG":"D11349","DRUGBANK_ID":"DB15097","PDB_CHEM_ID":" AF9","PUBCHEM_CID":"24764487","IUPHAR_LIGAND_ID":"9540","SECONDARY_CAS_RN":"2310299-91-1","MESH_SUPPLEMENTAL_RECORD_UI":"C000597312"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Msd K.K.","relationship":"Current Owner"}],"publicationCount":5,"therapeuticAreas":["Pain"],"_revenueScrapedAt":"2026-03-31 09:33:54.830088+00","atcClassification":{"source":"DrugCentral","atcCode":"R05DB29","allCodes":["R05DB29"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Msd K.K.","companyId":"msd-k-k","modality":"Small molecule","firstApprovalDate":"2023","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:52:36.219693+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}